We offer a wide range of services for COVID-19 clinical trials, including regulatory support, CPU Phase I unit, patient recruitment, end-to-end trial management, biometrics and infectious disease expertise. Find out more: https://www.sgs.com/en/campaigns/sgs-life-sciences-during-covid-19

1. REGULATORY SUPPORT
• 7 submitted projects for antiviral
products & vaccines
• 3 of those approved within 2 weeks
• 6 scientific advice meetings
• Short TAT in many EU countries and in the US
RECRUITMENT
• Network of 50+ sites with access
to different COVID-19 patient
populations (moderate to severe)
• Database > 10,000 healthy
volunteers
INFECTIOUS DISEASES EXPERTISE
• 450 projects in the last 10 years
• +35 years experience in
infectious diseases and vaccines
END-TO-END TRIAL MANAGEMENT
• Trial oversight processes fully compliant
with EMA & FDA COVID-19 guidelines
• First hand operational experience
with COVID-19 trials
• Effective remote trial solutions in place
BIOMETRICS CAPABILITIES
• CDISC knowledge on infectious disease
specific domains
• Full Support IDMC to ensure subject
safety and trial integrity
• Collect, analyze and present data in full
compliance with the relevant regulations
CPU PHASE I UNIT
• 4 days regulatory approval
• All safety measures implemented
• Fully operational2
• COVID-19 testing available
1
https://milkeninstitute.org/covid-19-tracker, June 2020
2
endorsed by CA, MEC/ IRB, local hospitals
MORE INFORMATION:
sgs.com/lifesciencescovid19
CONTACT US:
clinicalresearch@sgs.com
Partner with SGS for COVID-19 Clinical Trials
COVID-19
CLINICAL FACTS
1
• 227 drugs in preclinical or
clinical development
• 159 vaccines in preclinical
or clinical development
• 64 antibody therapies
in preclinical or clinical
development